CAT and breast carcinoma: Therefore, the presence of mCAT in PyMT cells appears to quench intracellular ROS making them less sensitive to the invasive promoting effects of ROS, and suggesting that targeting mitochondria within primary tumor cells with catalase is a potentially relevant clinical strategy to prevent, or at least slow the rate, of invasive breast cancer progression.